Polypeptide radionuclide complex of targeted fibroblast activating protein and application of polypeptide radionuclide complex
Patent Information
- Application Number
- CN202310528725.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-11
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2043-05-11
AI Technical Summary
The existing FAP-targeted therapeutic drugs have a short retention time in the tumor site, resulting in poor treatment effect and room for improvement in cell internalization and tumor uptake.
A class of peptide radionuclide complexes targeting fibroblast activation proteins were designed. By optimizing the combination of peptide sequence and chelating groups, the enzyme inhibitory activity and cellular affinity of the drug were improved, and the radionuclide labeling was achieved. Long tumor retention time.
It significantly improves the internalization rate of drugs and tumor intake, extends the tumor retention time, and enhances the therapeutic effect on tumors with high expression of FAP. It is suitable as a diagnostic and therapeutic method.
Smart Images

Figure CN118930606A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the fields of nuclear medicine and molecular imaging, and in particular to a polypeptide radionuclide complex targeting fibroblast activation protein and an application thereof. Background Art
[0002] Malignant tumors remain one of the major diseases that threaten human life and health, and how to achieve accurate diagnosis and treatment of tumors still faces great challenges. Malignant tumors are composed of tumor cells and various non-malignant cells, which form and shape the tumor microenvironment and tumor stroma. Since the stroma can account for 90% of the total tumor volume, in some cancers, targeted therapy against the stroma may be more sensitive than targeting tumor cells themselves. Cancer-associated fibroblasts (CAFs) are a heterogeneous population of fibroblast-like cells that constitute most of the tumor stroma and play an important role in tumor growth, migration, metastasis, extracellular matrix remodeling, treatment resistance and immunosuppression. Compared with cancer cells, CAFs are more genetically stable and less likely to develop treatment resistance, making them excellent target cells for anti-tumor therapy (Nat. Rev. Cancer 2016, 16, 582–598).
[0003] Fibroblast activation protein (FAP) is a type II membrane-bound glycoprotein that belongs to the dipeptidyl peptidase 4 (DPP4) family and has dipeptidyl peptidase and endopeptidase activities. Generally, FAP is only transiently expressed during embryonic development. In healthy humans, FAP is only expressed in granulation tissue, cervix, endometrium, pancreas, placenta, and skin during wound repair, and is not commonly or widely expressed in other healthy adult organs. When malignant tumors occur, fibroblasts are activated, and FAP is upregulated in activated fibroblasts. Studies have shown that fibroblast activation protein (FAP) is upregulated in more than 90% of epithelial tumor stroma. The expression specificity of FAP makes it a potential target for tumor diagnosis and treatment (Proteom. Clin. Appl. 2014, 8, 454–463).
[0004] In recent years, tumor-targeted therapeutic drugs for FAP have developed rapidly, and a variety of FAP-targeted therapeutic schemes have been developed and entered clinical trials. Among them, radioactive targeted FAP therapeutic drugs are particularly eye-catching. Radioactive targeted therapeutic drugs use small molecules, peptides, antibodies, etc. as targeting carriers, and deliver radionuclides to the tumor site through their specific targeting effects, releasing high-energy rays to kill tumor cells and achieve precision treatment. The Haberkorn Uwe research team at the University of Heidelberg in Germany has developed a series of quinoline-based small molecule radioactive drugs to target FAP for diagnosis and treatment. These FAP-targeted small molecule radioactive drugs show high specificity in various primary and metastatic tumors, but their tumor clearance rate is high, and more than 70% of the drugs are metabolized and cleared at the tumor site within 24 hours (WO2019154886A1; Eur.J.Nuc.Med Mol.Imag, 2022, 49, 3651–3667). The high tumor clearance rate shortens the treatment time of the drug and limits its potential tumor treatment effect. In 2020, 3B-Pharmaceuticals GmbH in Germany developed the FAP-targeted cyclic peptide FAP-2286, and coupled FAP-2286 with radionuclides (such as 177-Lu) for the treatment of solid tumors (WO 2022148843). Studies have shown that FAP-2286 has a higher tumor uptake rate, longer tumor retention time, and better tumor inhibition effect than FAP-targeted small molecules, and has now entered phase I / II studies (Eur. J. Nuc. Med Mol. Imag, 2022, 49, 3651–3667). Researchers in this field know that high target cell affinity can often reduce the dosage of radioactive targeted therapeutic drugs, increase drug absorption at the tumor site, and reduce radiation damage to non-target organs. In addition, the longer retention time of peptide-coupled radionuclide drugs at the tumor site often indicates better tumor treatment effects. Although FAP-2286 has shown a certain potential in tumor treatment, its cellular internalization rate, tumor uptake and tumor retention time still need to be improved. Therefore, based on the existing research on FAP targeting molecules, designing FAP targeting peptide radiotherapy drugs with novel structures, high uptake rates and reasonable metabolic properties is of great significance and market potential for tumor patients. Summary of the invention
[0005] The problem underlying the present invention is to provide compounds suitable as diagnostic (imaging) agents and / or medicaments, in particular if conjugated to diagnostically and / or therapeutically active effectors, such that the compounds are potent inhibitors of FAP activity. Another problem underlying the present invention is to provide compounds suitable as diagnostic agents and / or medicaments in the diagnosis and / or treatment of diseases, in particular if conjugated to diagnostically and / or therapeutically active effectors, wherein the diseased cells and / or diseased tissues express FAP. A further problem underlying the present invention is to provide a compound suitable for delivering diagnostically and / or therapeutically effective agents to diseased cells and / or diseased tissues, more particularly diseased cells and / or diseased tissues expressing FAP, respectively, preferably said diseased tissues comprising or containing cancer-associated fibroblasts. In addition, the problem underlying the present invention is to provide methods for diagnosing diseases, methods for treating and / or preventing diseases, and methods for combined diagnosis and treatment of diseases; preferably, such diseases are diseases involving cells and / or tissues expressing FAP, more particularly diseased cells and / or diseased tissues expressing FAP, preferably said diseased tissues comprising or containing cancer-associated fibroblasts. Furthermore, the problem underlying the present invention is to provide a pharmaceutical composition containing a compound having the above characteristics. Further, the problem underlying the present invention is to provide a kit suitable for use in any of the above methods.
[0006] Specifically, the purpose of the present invention is to provide the use of the targeted fibroblast activation protein (FAP) polypeptide complex in tumor radionuclide imaging and treatment.
[0007] Specific tumor applications include the diagnosis and treatment of basal cell carcinoma of the skin, oral squamous cell carcinoma, esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, prostate cancer, cervical cancer, ovarian cancer, bile duct cancer, renal cell carcinoma, salivary gland cancer, sarcoma, and bladder cancer.
[0008] The object of the present invention is to provide the structure of the compound targeting fibroblast activation protein (FAP).
[0009] Another object of the present invention is to provide a complex structure of the ligand of the targeted fibroblast activation protein (FAP) compound and a radionuclide label.
[0010] The present invention provides a class of fibroblast activation protein targeting compounds, which are at least one of the compounds having the structures shown in Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII and Formula IX: At least one of the compounds having the structures shown in Formula VIII and Formula IX:
[0011]
[0012]
[0013]
[0014] According to the present invention, Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX are combinations containing urea Glu(OH)2-CO-Lys and / or Q-CO-R and 7 amino acids AA1-AA2-AA3-AA4-AA5-AA6-AA7 and W to form a cyclic peptide, as well as compounds formed by them with a connecting group L and a chelating group C.
[0015] According to the present invention, in the structure Q-CO-R of the urea in formula II, formula VII, formula VIII, and formula IX, Q and R can be glycine, the same or different 19 natural L- or D-type amino acids, NH2-(CH2) n -COOH, NH2-(PEG) n -CH2COOH、NH2-(PEG) n -CH2CH2COOH, NH2CH3, NH2-(CH2) n -CH3、NH2-(PEG) n -CH3、NH2-(PEG) n -CH2CH3 is arbitrarily combined with amino groups to form a urea structure (n=1-18).
[0016] According to the present invention, the cyclic peptide sequence in Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII and Formula IX comprises 7 amino acids AA1-AA2-AA3-AA4-AA5-AA6-AA7, wherein the peptide sequence is described from the nitrogen end to the carbon end; wherein any one AA in AA1-AA2-AA3-AA4-AA5-AA6-AA7 is common glycine, L or D-Hyp, L- or D-type 1-Nal or 2-Nal, and 19 kinds of L-type natural amino acids and D-type non-natural amino acid residues. Specifically, AA1-AA2-AA3-AA4-AA5-AA6-AA7 is preferably Cys-Pro-Hyp-Thr-Gln-(1-Nal)-Cys or Cys-Pro-Hyp-Thr-Gln-(2-Nal)-Cys or Cys-Pro-Hyp-Thr-Gln-Trp-Cys.
[0017] According to the present invention, W is a cyclic structure formed by forming a thioether bond between tribromobenzylbenzene or dibromobenzylbenzene and the thiol groups contained in AA1 and AA7 in Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX. Alternatively, W may also represent a disulfide bond formed by direct oxidation of the thiol groups contained in AA1 and AA7.
[0018] According to the present invention, in Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX, L is a linking group, and specifically, L can be O, NH2CH2(CH2) n SH (n = 0-17, n = 1 is AET), Ahx, AEEA, rGlu, any one or a combination of 20 L-type natural amino acids or corresponding D-type amino acids, L- or D-type 1-Nal or 2-Nal, 4-amino-piperidine-4-carboxylic acid, 4-aminomethylbenzoic acid, 4-(aminomethyl)cyclohexanecarboxylic acid, 1-piperazine-(CH2) n A linking group formed by condensing COOH (n=0-18), AET-Ahx, AET-AEEA, AET-Ahx-rGlu, AET-Ahx–rGlu-AEEA, AET-AEEA-rGlu-Ahx, AET-AEEA-AEEA–Ahx, AET-Ahx–rGlu-AEEA-AEEA, AET-AEEA-AEEA–rGlu-Ahx, and any combination thereof with a peptide chain amino group or bromide and a chelating agent C.
[0019] According to the present invention, in Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, C is a group formed by a chelating agent. The chelating agent can be selected from DOTA, NOTA, NODA, NODAGA, DOTP, TETA, ATSM, PTSM, EDTA. More preferably, it is DOTA, DOTAGA, NOTA. Specifically, the selected chelating agent is DOTA, NOTA.
[0020] According to the present invention, in Formula I, Formula II, Formula III, Formula IV, Formula V, and Formula VI, X1 is a modification group formed by an amide bond at the nitrogen end of the cyclic peptide; specifically, X1 is preferably 0, acetic acid, propionic acid, phenylpropionic acid, hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, or isomeric acids thereof, octadecanedioic acid, Ph(CH2)nCOOH (n=0-17), or CH3O-(PEG) n -CH2COOH, CH3O-(PEG) n -CH2CH2COOH, CH3CH2O-(PEG) n -CH2COOH, CH3CH2O-(PEG) n -CH2CH2COOH (PEG = ethoxy, n = 1-16) or its isomers, and an amide residue formed with an amino group. Alternatively, X1 can also be a modification group formed by an amide bond of any amino acid in which an acetyl group blocks the amino group, including but not limited to Ac-Gly, Ac-Glu, Ac-Thr, Ac-Phe, or any combination thereof.
[0021] According to the present invention, Y1, Y2, X2 in Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX, and X1 in Formula VII, Formula VIII, and Formula IX are structural modification groups at both ends of the cyclic peptide, and the structures of Y1, Y2, X1, and X2 may be the same or different; Y1, Y2, X1, and X2 are 0, any amino acid, or a fragment formed by an amino acid and Ahx, AEEA, etc., including but not limited to Ahx, AEEA, Lys, 1-Nal, 2-N al, Trp, Glu, rGlu, Gly, Phe, Pca, Ahx-Ahx, AEEA-AEEA, Ahx-AEEA, Gly-Ahx, rGlu-Ahx, Gly-AEEA, rGlu-AEEA, Ahx-Ahx-Gly, Ahx-Ahx-rGlu, Ahx-AEEA-rGlu, 4-aminomethylbenzoic acid, 4-(aminomethyl)cyclohexanecarboxylic acid, and any combination thereof.
[0022] According to the present invention, in Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX, S is a linker fragment. Specifically, S can be O, glycine, 19 kinds of L-type natural amino acids or corresponding D-type amino acids or compounds containing amino and carboxyl groups, including but not limited to Ahx, AEEA, Lys, 1-Nal, 2-Nal, Gly, Glu, rGlu, and any combination thereof.
[0023] According to the present invention, the compound targeting fibroblast activation protein is more specifically the following compound: NRT-87
[0024] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET)-Phe-Gln-Thr-Pro-Pro-Cys]-Hex)-OH
[0025]
[0026] NRT-87D
[0027] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA)-Phe-Gln-Thr-Pro-Pro-Cys]-Hex)-OH
[0028]
[0029] NRT-136
[0030] Glu(OH)2NH-CO-Lys((2-Nal)-Lys-[Cys(SS)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0031]
[0032] NRT-136DGlu(OH)2NH-CO-Lys((2-Nal)-Lys(DOTA)-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0033]
[0034] NRT-137
[0035] Glu(OH)2NH-CO-Lys((2-Nal)-Lys-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0036]
[0037] NRT-137D
[0038] Glu(OH)2NH-CO-Lys((2-Nal)-Lys(DOTA)-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0039]
[0040] NRT-137B
[0041] Glu(OH)2NH-CO-Lys((2-Nal)-Lys-Ahx-(Cys(DBMB)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys)-Hex)-OH
[0042]
[0043] NRT-138
[0044] Glu(OH)2NH-CO-Lys((2-Nal)-Lys-AEEA-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0045]
[0046] NRT-138D
[0047] Glu(OH)2NH-CO-Lys((2-Nal)-Lys(DOTA)-AEEA-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0048]
[0049] NRT-139
[0050] Glu(OH)2NH-CO-Lys((1-Nal)-Lys-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0051]
[0052] NRT-139DGlu(OH)2NH-CO-Lys((1-Nal)-Lys(DOTA)-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0053]
[0054] NRT-143
[0055] Glu(OH)2NH-CO-Lys(Trp-Pca-Ahx-[Cys(S-S)-Phe-Gln-Thr-Pro-Pro-Cys]-Hex)-OH
[0056]
[0057] NRT-164
[0058] Glu(OH)2NH-CO-Lys(Trp-Lys-[Cys(S-S)-Trp-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0059]
[0060] NRT-165
[0061] Glu(OH)2NH-CO-Lys(Phe-Lys-[Cys(S-S)-Trp-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0062]
[0063] NRT-179
[0064] Glu(OH)2NH-CO-Lys(Glu-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Lys-Hex)-OH
[0065]
[0066] NRT-180
[0067] Glu(OH)2NH-CO-Lys(Glu-Lys-Gly-[Cys(S-S)-Trp-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0068]
[0069] NRT-181
[0070] Glu(OH)2NH-CO-Lys(Glu-Lys-Gly-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0071]
[0072] NRT-185
[0073] Glu(OH)2NH-CO-Lys(Glu-Lys-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0074]
[0075] NRT-186
[0076] Glu(OH)2NH-CO-Lys(Glu-Phe-Lys-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0077]
[0078] NRT-189
[0079] Glu(OH)2-CO-Lys(2-Nal-Gly-Lys-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0080]
[0081] NRT-190
[0082] Glu(OH)2-CO-Lys((1-Nal)-Lys-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0083]
[0084] NRT-191
[0085] Glu(OH)2NH-CO-Lys((1-Nal)-Lys-Ahx-[Cys(S-S)-(2-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0086]
[0087] NRT-219
[0088] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0089]
[0090] NRT-219D
[0091] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0092]
[0093] NRT-219L1
[0094] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-Ahx-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0095]
[0096] NRT-219L2
[0097] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-AEEA-AEEA-Ahx-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0098]
[0099] NRT-219L3
[0100] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-AEEA-AEEA-rGlu-Ahx-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0101]
[0102] NRT-220
[0103] Glu(OH)2NH-CO-Lys(AEEA-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0104]
[0105] NRT-220D
[0106] Glu(OH)2NH-CO-Lys(AEEA-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0107]
[0108] NRT-221
[0109] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Gly-OH
[0110]
[0111] NRT-221D
[0112] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Gly-OH
[0113]
[0114] NRT-222
[0115] Glu(OH)2NH-CO-Lys(Gly-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0116]
[0117] NRT-223
[0118] Glu(OH)2NH-CO-Lys(Ahx-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0119]
[0120] NRT-223D
[0121] Glu(OH)2NH-CO-Lys(Ahx-Ahx-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0122]
[0123] NRT-224
[0124] Glu(OH)2NH-CO-Lys(Ahx-Gly-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0125]
[0126] NRT-225
[0127] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Glu-OH
[0128]
[0129] NRT-226
[0130] Glu(OH)2NH-CO-Lys(Ahx-Glu-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0131]
[0132] NRT-226D
[0133] Glu(OH)2NH-CO-Lys(Ahx-Glu-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0134]
[0135] NRT-227
[0136] Glu(OH)2NH-CO-Lys(Ahx-Ahx-Glu-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0137]
[0138] NRT-228
[0139] Glu(OH)2NH-CO-Lys(Ahx-AEEA-Glu-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0140]
[0141] NRT-230
[0142] Glu(OH)2NH-CO-Lys(Ac)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu-OH
[0143]
[0144] NRT-231
[0145] Glu(OH)2NH-CO-Lys(Hex)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu-OH
[0146]
[0147] NRT-232
[0148] Glu(OH)2NH-CO-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu-OH
[0149]
[0150] NRT-233
[0151] Glu(OH)2NH-CO-Ahx-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu-OH
[0152]
[0153] NRT-234
[0154] Glu(OH)2NH-CO-Lys(Hex)-Gly-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu-OH
[0155]
[0156] NRT-235
[0157] Glu(OH)2NH-CO-Lys(Hex)-AEEA-[Cys(TBMB-AET)-Pro-Hyp-Thr-Glu-(1-Nal)-Cys]-Glu
[0158]
[0159] NRT-236
[0160] Glu(OH)2NH-CO-Lys(PPA)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu
[0161]
[0162] NRT-237
[0163] Glu(OH)2NH-CO-Lys(PA)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu
[0164]
[0165] NRT-238
[0166] Glu(OH)2NH-CO-Lys(CH3PEG2)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu
[0167]
[0168] NRT-239
[0169] Glu(OH)2NH-CO-Lys(Glu-Gly-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0170]
[0171] NRT-240
[0172] Glu(OH)2NH-CO-Lys(Glu-Ahx-Gly-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0173]
[0174] NRT-241
[0175] Glu(OH)2NH-CO-Lys(Glu-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0176]
[0177] NRT-242
[0178] Glu(OH)2NH-CO-Lys(Gly-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0179]
[0180] NRT-243
[0181] Glu(OH)2NH-CO-Lys(Gly-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Glu-OH
[0182]
[0183] NRT-244
[0184] Glu(OH)2NH-CO-Lys(Glu-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Glu-OH
[0185]
[0186] According to the present invention, the compound targeting fibroblast activation protein can also be labeled with radionuclides to obtain a polypeptide radionuclide complex targeting fibroblast activation protein; specifically, the polypeptide radionuclide complex targeting fibroblast activation protein is a complex obtained by labeling a radionuclide with a compound of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, or formula IX of the present invention as a ligand; the radionuclides include: 89 Zr, 44 Sc, 111 ln, 90 Y. 66 Ga, 67 Ga, 68 Ga, 177 Lu, 99m Tc, 64 Cu, 67 Cu, 149 Tb, 152 Tb, 161 Tb, 203 Pb, 212 Pb, 153 Gd, 155 Gd, 123 I. 125 I. 131 I. 18 F. 157 Gd, 213 Bi, 225 Ac, 230 U. 223 Ra, 165 2. 18 F and 177 More specifically, the radionuclide used for diagnosis is preferably 64 Cu, 68 Ga,89 Zr, 99m Tc, 111 ln and 18 F. The radionuclide used for treatment is preferably 90 Y. 177 Lu, 255 Ac.
[0187] According to the present invention, the compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX or their pharmaceutically acceptable salts can be used to prepare radionuclide therapy or imaging drugs for tumors with high FAP protein expression.
[0188] According to the present invention, the polypeptide radionuclide complex targeting fibroblast activation protein can be applied to the radionuclide therapy or imaging of tumors with high expression of FAP protein.
[0189] According to the present invention, a composition is also provided, comprising a compound according to Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, a polypeptide radionuclide complex targeting fibroblast activation protein, and a pharmaceutically acceptable excipient. The composition can be applied to the radionuclide therapy or imaging of tumors with high expression of FAP protein.
[0190] According to the present invention, the above-mentioned compound, complex or composition is prepared into an injection, which is administered by intravenous injection for patients with tumors with high expression of FAP protein; the tumors with high expression of FAP protein include but are not limited to basal cell carcinoma of the skin, oral squamous cell carcinoma, esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, prostate cancer, cervical cancer, ovarian cancer, bile duct cancer, renal cell carcinoma, salivary gland cancer, sarcoma, and bladder cancer.
[0191] According to the present invention, a pharmaceutical kit is also provided, which comprises the above-mentioned compound, complex composition, one or more optional excipients and one or more devices optionally present, wherein the device is selected from a labeling device, a purification device, a manipulation device, a radiation protection device, an analysis device or an administration device.
[0192] One skilled in the art will recognize that one or the compound of the present invention is any compound disclosed herein, including but not limited to any compound described in any of the above embodiments and any of the following embodiments.
[0193] One skilled in the art will recognize that one or the method of the present invention is any method disclosed herein, including but not limited to any method described in any of the above embodiments and any of the following embodiments.
[0194] One skilled in the art will recognize that one or the composition of the present invention is any composition disclosed herein, including but not limited to any composition described in any of the above embodiments and any of the following embodiments.
[0195] One skilled in the art will recognize that one or the kit of the present invention is any kit disclosed herein, including but not limited to any kit described in any of the above embodiments and any of the following embodiments.
[0196] The present invention introduces a highly polar hydrophilic fragment Glu-CO-Lys at the carbon end of the cyclic peptide to change the molecular properties, and then reasonably selects the connecting fragment, combined with reasonable modifications of other sites, and finally obtains a candidate molecule with higher enzyme inhibition activity, better cell affinity and longer tumor retention time.
[0197] The present invention provides a polypeptide radionuclide complex targeting fibroblast activation protein and its application. The biological test results show that the complex has higher enzyme inhibition activity, better cell affinity, higher tumor uptake and longer maintenance time, and is suitable for radionuclide therapy and imaging of tumors with high expression of FAP protein. BRIEF DESCRIPTION OF THE DRAWINGS
[0198] Figure 1 for 68 Ga-FAP-2286, 68 Ga-NRT-136D, 68 Ga-NRT-137D, 68 Ga-NRT-138D cell affinity test in FAP-positive cell line U87;
[0199] Figure 2 for 68 Ga-FAP-2286, 68 Ga-NRT-136D, 68 Ga-NRT-137D, 68 Ga-NRT-138D cell affinity test in FAP-positive cell line HEK-293-FAP;
[0200] Figure 3 for 68 Ga-FAP-2286, 68 Ga-NRT-219D, 68 Ga-NRT-220D, 68 Ga-NRT-221D cell affinity test in FAP-positive cell line U87;
[0201] Figure 4 for 68 Ga-FAP-2286,68 Ga-NRT-219D, 68 Ga-NRT-220D, 68 Ga-NRT-221D cell affinity test in FAP-positive cell line HEK-293-FAP;
[0202] Figure 5 for 177 SPECT imaging results of Lu-FAP-2286 in tumor model mice;
[0203] Figure 6 for 177 SPECT imaging results of Lu-NRT-219D in tumor model mice. DETAILED DESCRIPTION
[0204] Synthesis of polypeptide: The fibroblast activation protein ligand polypeptide involved in the present invention is synthesized by a solid phase peptide synthesis method based on Fmoc.
[0205] The solid phase synthesis method of Glu-CO-Lys urea structure is as follows: 3 mmol of di(tert-butyl)-L-glutamic acid hydrochloride in dry dichloromethane solution (200 mL) and 3 mL of N-ethyldiisopropylamine (DIPEA) are slowly added dropwise to 1 mmol of triphosgene in dry dichloromethane solution (10 mL) at 5°C. After the addition is complete, the reaction is continued for 3 hours, and then the reaction solution is added to 0.5 mmol of Lys(Alloc)-CTC resin and the reaction is continued for 16 hours under gentle stirring. Then 50 mg of tetrakis(triphenylphosphine)palladium and 400 μL of morpholine are added, and the reaction is continued for 3 hours to remove the Alloc protecting group.
[0206] The connection of other amino acid fragments was continued in sequence by solid phase synthesis of linear peptides according to the Fmoc solid phase peptide synthesis method.
[0207] After the solid phase synthesis of the linear peptide is completed, a cleavage solution containing ethanedithiol is added for cleavage. After the cleavage is completed, methyl tert-butyl ether is used for precipitation, the solid is separated by centrifugation, the supernatant is discarded, and the crude linear peptide is obtained by vacuum drying.
[0208] Preparation of cyclic peptides:
[0209] Cyclization method 1: Dissolve the crude peptide (about 100 mg) in 100 mL of a 1:1 mixed solution of ammonium bicarbonate solution (50 mM, pH = 8.5) and acetonitrile. Add 1.5 equivalents of 1,3,5-tris(bromomethyl)benzene to the mixture. Stir the solution for 1 hour, add 10 equivalents of β-mercaptoethylamine and continue the reaction for 2 hours. After the reaction is completed, purify by preparative HPLC and freeze-dry to obtain the product.
[0210] Cyclization method 2: The crude peptide (about 100 mg) was dissolved in 100 mL of a 1:1 mixed solution of ammonium bicarbonate solution (50 mM, pH = 8.5) and acetonitrile. 1.1 equivalents of 1,3-di(bromomethyl)benzene were added to the mixture, and the solution was stirred for 1 hour. After the reaction was completed, it was purified by preparative HPLC and lyophilized to obtain the product.
[0211] Cyclization method 3: disulfide bond cyclization Dissolve 50 μmol of the crude cleaved linear peptide in 60 mL of a 1:1 mixed solvent of acetonitrile and ammonium acetate buffer (0.1 M), add 50 μmol of [Pt(en)2Cl2]Cl2 (dichloro-bis(ethylenediamine)-platinum(IV)] chloride), and continue stirring the reaction. After the cyclization reaction is completed by LC-MS monitoring, purify by preparative HPLC and freeze-dry to obtain the product.
[0212] Connection of chelating group C:
[0213] 20 μmol of the cyclic peptide intermediate was dissolved in 300 μl of DMSO, and 5 μL of diisopropylethylamine was added, followed by addition of a DMSO solution (200 μL) of DOTA-NHS (30 μmol), and the reaction was stirred at room temperature and monitored by LCMS until the reaction was completed.
[0214] The known fibroblast activation protein inhibitor FAP-2286 (developed by 3B-Pharmaceuticals GmbH, Germany) involved in the present invention is synthesized by a linear peptide based on the Fmoc solid phase peptide synthesis method. The synthesis of FAP-2286 is completed by using the cyclization method 1 and the connection method of the chelating group C described in the present invention.
[0215] Table 1 Abbreviations, names and structures of chemical groups in the present invention
[0216]
[0217]
[0218]
[0219]
[0220]
[0221]
[0222]
[0223] Table 2 Sequences, calculated molecular masses and accurate measured molecular masses of compounds determined by LCMS
[0224]
[0225]
[0226]
[0227]
[0228]
[0229] Example: Nuclide labeling
[0230] 68 Ga labeling
[0231] Take 500 μL of buffer (1.2M sodium acetate aqueous solution) to the vial, add 4 μL of NRT-87D aqueous solution (1mM / L), and then add 200 μL of about 1mCi 68 GaCl3 solution (eluted from germanium gallium generator) was placed on a preheated heater at 95°C for 15 min, then cooled for 5 min after stopping heating, and the radiochemical purity was determined by Radio-HPLC.
[0232] This example also uses the same labeling method to label FAP-2286D, NRT-136D, NRT-137D, NRT-138D, NRT-219D, NRT-220D, and NRT-221D. 68 The Ga mark is not described in detail here.
[0233] 68 Ga-NRT-87D
[0234] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 68 Ga)-Phe-Gln-Thr-Pro-Pro-Cys]-Hex)-OH
[0235]
[0236] 68 Ga-NRT-136D
[0237] Glu(OH)2NH-CO-Lys((2-Nal)-Lys(DOTA- 68 Ga)-[Cys(SS)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0238]
[0239] 68 Ga-NRT-137D
[0240] Glu(OH)2NH-CO-Lys((2-Nal)-Lys(DOTA- 68 Ga)-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0241]
[0242] 68 Ga-NRT-138DGlu(OH)2NH-CO-Lys((2-Nal)-Lys(DOTA- 68 Ga)-AEEA-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0243]
[0244] 68 Ga-NRT-219D
[0245] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 68 Ga)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0246]
[0247] 68 Ga-NRT-220DGlu(OH)2NH-CO-Lys(AEEA-[Cys(TBMB-AET-DOTA- 68 Ga)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0248]
[0249] 68 Ga-NRT-221D
[0250] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 68 Ga)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Gly-OH
[0251]
[0252] 68 Ga-FAP-2286
[0253] Hex-[Cys(TBMB-AET-DOTA- 68 Ga)-Pro-Pro-Thr-Gln-Phe-Cys]-OH
[0254]
[0255] 177 Lu's mark:
[0256] Mix 25 μL of NRT-87D aqueous solution (1 mM / L) with 175 μL of 0.5 M sodium acetate buffer and 0.5 M sodium ascorbate buffer (pH = 4.5). 177 Lu (about 3.5 mCi) solution was mixed therewith and heated to 95°C for 20 minutes, cooled for 5 minutes, and the radiochemical purity was determined by Radio-HPLC.
[0257] This example also uses the same labeling method to label NRT-219D and FAP-2286. 177 Lu mark, no further description is given here.
[0258] 177 Lu-NRT-87D
[0259] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 177 Lu)-Phe-Gln-Thr-Pro-Pro-Cys]-Hex)-OH
[0260]
[0261] 177 Lu-NRT-219D
[0262] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 177 Lu)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH
[0263]
[0264] 177 Lu-FAP-2286
[0265] Hex-[Cys(TBMB-AET-DOTA-177 Lu)-Pro-Pro-Thr-Gln-Phe-Cys]-OH
[0266]
[0267] Radiochemical purity analysis method:
[0268] The radiochemical purity of the radionuclide-labeled compound was determined by connecting a high performance liquid chromatograph to a radioactive detector (Radio-HPLC). Instruments: Ultra-high performance liquid chromatograph (ACQUIY ARCUHPLC, Waters), radioactive thin layer scanner (MS-2000FP, Ecker & Ziegler). Mobile phase: 0.1% trifluoroacetic acid aqueous solution and acetonitrile.
[0269] FAP half inhibitory concentration IC50 test:
[0270] Recombinant human FAP (Acro, FAP-H5244) was diluted to a concentration of 0.4 nM in assay buffer (50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 0.1 mg / ml (0.01%) BSA, pH 7.4). 40 μl of FAP solution was mixed with 100 nl of 3-fold serially diluted test compounds and centrifuged at 1000 rpm for 1 min. Z-Gly-Pro-AMC (CAS: 68542-93-98) substrate was then added at a final concentration of 10 uM, centrifuged at 1000 rpm for 1 min, and sealed in a black 384-well opaque black plate (PerkinElmer) and incubated at room temperature for 60 minutes. After centrifugation at 1000 rpm for 1 min, the plate was read on Envision. FAP can hydrolyze the fluorescent substrate Z-Gly-Pro-AMC to generate highly fluorescent AMC. The emission wavelength of AMC is between 390-460nM. The fluorescence signal value can be easily detected through the program set on Envision. Four-parameter logistic (4PL) curve fitting and IC50 calculation are performed using Prism software. Calculation of IC50 value: Import the inhibition rate value of each concentration of the compound into GraphpadPrism, perform concentration effect curve fitting and IC50 value calculation, Prism S-type curve fitting formula: log (inhibitor) vs. response--Variable slope: Y = Bottom + (Top-Bottom) / (1 + 10^((LogIC50-X)*HillSlope)).
[0271] Table 3 FAP half inhibitory concentration of peptide sequences
[0272]
[0273]
[0274]
[0275] Cell affinity test:
[0276] The cultured U87 and HEK-293-FAP were digested with 0.25% trypsin (Hyclone SH30042.01), and the cells were collected and washed with 4°C 1× PBS buffer (Hyclone SH30256.01). After counting, they were prepared with complete DMEM medium (DMEM medium, Hyclone SH30243.01; 10% FBS, Gibco 10100147; 1% double antibody, Hyclone SV30010) to make 1×10 5 The cells were inoculated into 6-well plates, 1 mL per well, and the experiment was performed after 24 hours of adhesion. After 24 hours, the medium in the wells was replaced with 2 mL of serum-free DMEM medium (Hyclone SH30243.01) and incubated for 2 hours. After 2 hours, the medium was aspirated and 1 mL of serum-free DMEM medium (Hyclone SH30243.01) was added. Then, the cells were added into the 6-well plates. 68 Ga-labeled test substance 68 Ga-NRT-136D, shake well after adding the sample, and incubate at 37°C, 5% CO2 for 1 hour. After incubation, wash each well of cells with PBS solution (Hyclone SH30256.01) until the washing solution is radioactive. Lyse the cells with 0.5mL 1M sodium hydroxide (Macklin S817974-1L), then wash twice with 0.5mL PBS solution (Hyclone SH30256.01), collect the sodium hydroxide solution and PBS solution, and count them in a γ counter. Cell uptake is calculated as the percentage of radioactivity bound to the cell and the initial addition: AD%.
[0277] This example also uses the same cell affinity test method to test 68 Ga-labeled test substance 68 Ga-FAP-2286, 68 Ga-NRT-137D, 68 Ga-NRT-138D, 68 Ga-NRT-219D, 68 Ga-NRT-220D, 68 Ga-NRT-221D was subjected to cell affinity testing, which will not be described in detail here.
[0278] Depend on Figure 1 and Figure 2 visible, 68 Ga-NRT-136D, 68 Ga-NRT-137D, 68 The uptake of the three compounds of Ga-NRT-138D in two FAP-positive cell lines, U87 and HEK-293-FAP, was significantly better than that of the positive compound FAP-2286. 68 The uptake of Ga-NRT-136D in HEK-293-FAP was about 6.3 times that of FAP-2286 in Yangshen, which was significantly better than FAP-2286.
[0279] Depend on Figure 3 and Figure 4 visible, 68 The uptake of Ga-NRT-219D in two FAP-positive cell lines, U87 and HEK-293-FAP, was significantly better than that of positive compounds. 68 Ga-FAP-2286, 68 The uptake of Ga-NRT-219D in U87 cell line was approximately 68 5.0 times that of Ga-FAP-2286.
[0280] SPECT-CT imaging:
[0281] The cultured HEK-293-FAP cells were digested with 0.25% trypsin, and the cells were collected and washed with 4°C PBS buffer. After counting, the cells were prepared into 2×10 7 Female NOG mice (18-22 g, 6-8 weeks old) were fed adaptively for 3 days, anesthetized with isoflurane, the right hind limbs were shaved, and 100 μl of cell suspension was inoculated subcutaneously. 3 After the mice were fixed, the test substance (200 μCi) was injected into the mice via tail vein injection, and SPECT / CT imaging was performed at 24h, 48h and 72h after injection.
[0282] Depend on Figure 5 and Figure 6 visible, 177 Lu-NRT-219D accumulates significantly in the tumor site of mice, and the tumor imaging is clearly visible within 24-72 hours. 177 Lu-FAP-2286, 177 Imaging results of Lu-NRT-219D at 48 and 72 hours showed that its tumor uptake was higher and maintained longer.
[0283] Although the present invention has been described in detail above by means of general description, specific implementation methods and tests, it is obvious to those skilled in the art that some modifications or improvements may be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.
Claims
1. The targeted fibroblast activation protein compound has at least one of the structural compounds shown in Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII and Formula IX: in, In the structure Q-CO-R of the urea in formula II, formula VII, formula VIII, and formula IX, Q and R are glycine, the same or different 19 natural L- or D-type amino acids, NH 2 -(CH 2 ) n -COOH, NH2-(PEG) n -CH 2 COOH、NH 2 -(PEG) n -CH 2 CH 2 COOH、NH 2 CH 3 NH 2 -(CH 2 ) n -CH 3 、NH2-(PEG) n -CH 3 NH 2 -(PEG) n -CH 2 CH 3 Any combination of urea structures (n=1-18) formed by amino groups; Any one of AA1-AA2-AA3-AA4-AA5-AA6-AA7 is common glycine, L- or D-Hyp, L- or D-form 1-Nal or 2-Nal, 19 L-form natural amino acids, and D-form non-natural amino acid residues; W is a cyclic structure formed by forming a thioether bond between tribromobenzylbenzene or dibromobenzylbenzene and the thiol groups contained in AA1 and AA7; or, W is a disulfide bond generated by direct oxidation of the sulfhydryl groups contained in AA1 and AA7; L is a linking group; C is a group formed by a chelating agent; In Formula I, Formula II, Formula III, Formula IV, Formula V and Formula VI, X1 is a modification group formed by an amide bond at the nitrogen end of the cyclic peptide or a modification group formed by an amide bond of any amino acid whose amino group is blocked by an acetyl group, or any combination thereof; In Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX, Y1, Y2, and X2, and in Formula VII, Formula VIII, and Formula IX, X1 are structural modification groups at both ends of the cyclic peptide; S is a connecting fragment.
2. The compound according to claim 1, Features: The AA1-AA2-AA3-AA4-AA5-AA6-AA7 is Cys-Pro-Hyp-Thr-Gln-(1-Nal)-Cys or Cys-Pro-Hyp-Thr-Gln-(2-Nal)-Cys or Cys-Pro-Hyp-Thr-Gln-Trp-Cys.
3. The compound according to claim 1, Features: The L is a connecting group, specifically 0, NH 2 CH 2 (CH 2 ) n SH (n = 0-17, n = 1 is AET), Ahx, AEEA, rGlu, Gly, 19 any one or a combination of L-type natural amino acids or corresponding D-type amino acids, L- or D-type 1-Nal or 2-Nal, 4-amino-piperidine-4-carboxylic acid, 4-aminomethylbenzoic acid, 4-(aminomethyl)cyclohexanecarboxylic acid, 1-piperazine-(CH 2 ) n A linking group formed by condensing COOH (n=0-18), AET-Ahx, AET-AEEA, AET-Ahx-rGlu, AET-Ahx–rGlu-AEEA, AET-AEEA-rGlu-Ahx, AET-AEEA-AEEA–Ahx, AET-Ahx–rGlu-AEEA-AEEA, AET-AEEA-AEEA–rGlu-Ahx, and any combination thereof with a peptide chain amino group or bromide and a chelating agent C.
4. The compound according to claim 1, Features: The chelating agent is selected from DOTA, NOTA, NODA, NODAGA, DOTP, TETA, ATSM, PTSM, and EDTA.
5. The compound according to claim 1, Features: In formula I, formula II, formula III, formula IV, formula V, and formula VI, X1 is a modification group formed by an amide bond at the nitrogen end of the cyclic peptide; specifically, X1 is O, acetic acid, propionic acid, phenylpropionic acid, hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, or isomeric acids thereof, octadecanedioic acid, Ph(CH 2 )nCOOH (n = 0-17), or CH 3 O-(PEG) n -CH 2 COOH, CH 3 O-(PEG) n -CH 2 CH 2 COOH, CH 3 CH 2 O-(PEG) n -CH 2 COOH, CH 3 CH 2 O-(PEG)- n -CH 2 CH 2 COOH (PEG = ethoxy, n = 1-16) or its isomers, and an amide residue formed with an amino group; or, X1 is a modification group formed by an amide bond of any amino acid in which an acetyl group blocks the amino group, including but not limited to Ac-Gly, Ac-Glu, Ac-Thr, Ac-Phe, or any combination thereof.
6. The compound according to claim 1, Features: In Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX, Y1, Y2, X2, and X1 in Formula VII, Formula VIII, and Formula IX are structural modification groups at both ends of the cyclic peptide, and the structures of Y1, Y2, X1, and X2 may be the same or different; Y1, Y2, X1, and X2 are 0, any amino acid, or a fragment formed by an amino acid and Ahx, AEEA, etc., including but not limited to Ahx, AEEA, Lys, 1-Nal, 2-Nal, Trp, Glu, rGlu, Gly, Phe, Pca, Ahx-Ahx, AEEA-AEEA, Ahx-AEEA, Gly-Ahx, rGlu-Ahx, Gly-AEEA, rGlu-AEEA, Ahx-Ahx-Gly, Ahx-Ahx-rGlu, Ahx-AEEA-rGlu, 4-aminomethylbenzoic acid, 4-(aminomethyl)cyclohexanecarboxylic acid, and any combination thereof.
7. The compound according to claim 1, Features: In Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX, S is a linker fragment. Specifically, S is O, glycine, 19 kinds of L-type natural amino acids or corresponding D-type amino acids or compounds containing amino and carboxyl groups, including but not limited to Ahx, AEEA, Lys, 1-Nal, 2-Nal, Gly, Glu, rGlu, and any combination thereof.
8. A compound according to any one of claims 1 to 7, Features: The compound is selected from: NRT-87 Glu(OH) 2 NH-CO-Lys(Ahx-[Cys(TBMB-AET)-Phe-Gln-Thr-Pro-Pro-Cys]-Hex)-OH NRT-87D Glu(OH) 2 NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA)-Phe-Gln-Thr-Pro-Pro-Cys]-Hex)-OH NRT-136 Glu(OH) 2 NH-CO-Lys((2-Nal)-Lys-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-136D Glu(OH) 2 NH-CO-Lys((2-Nal)-Lys(DOTA)-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-137 Glu(OH) 2 NH-CO-Lys((2-Nal)-Lys-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-137D Glu(OH) 2 NH-CO-Lys((2-Nal)-Lys(DOTA)-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-137B Glu(OH) 2 NH-CO-Lys((2-Nal)-Lys-Ahx-(Cys(DBMB)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys)-Hex)-OH NRT-138 Glu(OH) 2 NH-CO-Lys((2-Nal)-Lys-AEEA-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-138D Glu(OH) 2 NH-CO-Lys((2-Nal)-Lys(DOTA)-AEEA-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-139 Glu(OH) 2 NH-CO-Lys((1-Nal)-Lys-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-139D Glu(OH) 2 NH-CO-Lys((1-Nal)-Lys(DOTA)-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-143 Glu(OH) 2 NH-CO-Lys(Trp-Pca-Ahx-[Cys(S-S)-Phe-Gln-Thr-Pro-Pro-Cys]-Hex)-OH NRT-164 Glu(OH) 2 NH-CO-Lys(Trp-Lys-[Cys(S-S)-Trp-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-165 Glu(OH) 2 NH-CO-Lys(Phe-Lys-[Cys(S-S)-Trp-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-179 Glu(OH) 2 NH-CO-Lys(Glu-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Lys-Hex)-OH NRT-180 Glu(OH) 2 NH-CO-Lys(Glu-Lys-Gly-[Cys(S-S)-Trp-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-181 Glu(OH) 2 NH-CO-Lys(Glu-Lys-Gly-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-185 Glu(OH) 2 NH-CO-Lys(Glu-Lys-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-186 Glu(OH) 2 NH-CO-Lys(Glu-Phe-Lys-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-189 Glu(OH) 2 -CO-Lys(2-Nal-Gly-Lys-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-190 Glu(OH) 2 -CO-Lys((1-Nal)-Lys-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-191 Glu(OH) 2 NH-CO-Lys((1-Nal)-Lys-Ahx-[Cys(S-S)-(2-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-219 Glu(OH) 2 NH-CO-Lys(Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-219D Glu(OH) 2 NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-219L1 Glu(OH) 2 NH-CO-Lys(Ahx-[Cys(TBMB-AET-Ahx-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-219L2 Glu(OH) 2 NH-CO-Lys(Ahx-[Cys(TBMB-AET-AEEA-AEEA-Ahx-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-219L3 Glu(OH) 2 NH-CO-Lys(Ahx-[Cys(TBMB-AET-AEEA-AEEA-rGlu-Ahx-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-220 Glu(OH) 2 NH-CO-Lys(AEEA-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-220D Glu(OH) 2 NH-CO-Lys(AEEA-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-221 Glu(OH) 2 NH-CO-Lys(Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Gly-OH NRT-221D Glu(OH) 2 NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Gly-OH NRT-222 Glu(OH) 2 NH-CO-Lys(Gly-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-223 Glu(OH) 2 NH-CO-Lys(Ahx-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-223D Glu(OH) 2 NH-CO-Lys(Ahx-Ahx-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-224 Glu(OH) 2 NH-CO-Lys(Ahx-Gly-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-225 Glu(OH) 2 NH-CO-Lys(Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Glu-OH NRT-226 Glu(OH) 2 NH-CO-Lys(Ahx-Glu-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-226D Glu(OH) 2 NH-CO-Lys(Ahx-Glu-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-227 Glu(OH) 2 NH-CO-Lys(Ahx-Ahx-Glu-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-228 Glu(OH) 2 NH-CO-Lys(Ahx-AEEA-Glu-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-230 Glu(OH) 2 NH-CO-Lys(Ac)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)- Cys]-Glu-OH NRT-231 Glu(OH) 2 NH-CO-Lys(Hex)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu-OH NRT-232 Glu(OH) 2 NH-CO-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu-OH NRT-233 Glu(OH) 2 NH-CO-Ahx-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu-OH NRT-234 Glu(OH) 2 NH-CO-Lys(Hex)-Gly-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu-OH NRT-235 Glu((OH) 2 NH-CO-Lys(Hex)-AEEA-[Cys(TBMB-AET)-Pro-Hyp-Thr-Glu-(1-Nal)-Cys]-Glu NRT-236 Glu(OH) 2 NH-CO-Lys(PPA)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu NRT-237 Glu(OH) 2 NH-CO-Lys(PA)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu NRT-238 Glu(OH) 2 NH-CO-Lys(CH 3 PEG2)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu NRT-239 Glu(OH) 2 NH-CO-Lys(Glu-Gly-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-240 Glu(OH) 2 NH-CO-Lys(Glu-Ahx-Gly-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-241 Glu(OH) 2 NH-CO-Lys(Glu-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-242 Glu(OH) 2 NH-CO-Lys(Gly-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-243 Glu(OH) 2 NH-CO-Lys(Gly-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Glu-OH NRT-244 Glu(OH) 2 NH-CO-Lys(Glu-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Glu-OH 9. A polypeptide radionuclide complex targeting fibroblast activation protein, which is a complex obtained by labeling a radionuclide with a compound according to any one of claims 1 to 8 as a ligand; the radionuclide comprises: 89 Zr, 44 Sc, 111 ln, 90 Y. 66 Ga, 67 Ga, 68 Ga, 177 Lu, 99m Tc, 64 Cu, 67 Cu, 149 Tb, 152 Tb, 161 Tb, 203 Pb, 212 Pb, 153 Gd, 155 Gd, 123 I. 125 I. 131 I. 18 F. 157 Gd, 213 Bi, 225 Ac, 230 U. 223 Ra, 165 2. 18 F and 177 Lu; the radionuclides used for diagnosis are 64 Cu, 68 Ga, 89 Zr, 99m Tc, 111 ln, 18 F, the radionuclide used for treatment is 90 Y. 177 Lu, 255 Ac.
10. A polypeptide radionuclide complex targeting fibroblast activation protein, the structural formula of which is shown below: 68 Ga-NRT-87D Glu(OH) 2 NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 68 Ga)-Phe-Gln-Thr-Pro-Pro-Cys]-Hex)-OH 68 Ga-NRT-136D Glu(OH) 2 NH-CO-Lys((2-Nal)-Lys(DOTA- 68 Ga)-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH 68 Ga-NRT-137D Glu(OH) 2 NH-CO-Lys((2-Nal)-Lys(DOTA- 68 Ga)-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH 68 Ga-NRT-138D Glu(OH) 2 NH-CO-Lys((2-Nal)-Lys(DOTA- 68 Ga)-AEEA-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH <h2 style=";text-align:left;direction:ltr"> 68 <h2 style=";text-align:left;direction:ltr"> Ga-NRT-219D Glu(OH) 2 NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 68 Ga)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH 68 Ga-NRT-220D Glu(OH) 2 NH-CO-Lys(AEEA-[Cys(TBMB-AET-DOTA- 68 Ga)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH 68 Ga-NRT-221D Glu(OH) 2 NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 68 Ga)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Gly-OH 177 Lu-NRT-87D Glu(OH) 2 NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 177 Lu)-Phe-Gln-Thr-Pro-Pro-Cys]-Hex)-OH <h2 style=";text-align:left;direction:ltr"> 177 <h2 style=";text-align:left;direction:ltr"> Lu-NRT-219D Glu(OH) 2 NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 177 Lu)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH 11. Use of the compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof in the preparation of a radionuclide therapy or imaging drug for tumors with high expression of FAP protein.
12. Use of the complex according to claim 9 or 10 in radionuclide therapy or imaging of tumors with high expression of FAP protein.
13. A composition, wherein the composition comprises the compound, complex and pharmaceutically acceptable excipient according to any one of claims 1 to 8, 9 and 10.
14. Use of the composition according to claim 13 in radionuclide therapy or imaging of tumors with high expression of FAP protein.
15. The use according to any one of claims 11, 12 or 14, Features: The compound, complex or composition is prepared into an injection and administered by intravenous injection for patients with tumors with high expression of FAP protein; the tumors with high expression of FAP protein include but are not limited to basal cell carcinoma of the skin, oral squamous cell carcinoma, esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, prostate cancer, cervical cancer, ovarian cancer, bile duct cancer, renal cell carcinoma, salivary gland cancer, sarcoma, and bladder cancer.
16. A kit comprising a compound according to any one of claims 1-8, 9, 10, 13, a complex composition, one or more optional excipients, and optionally one or more devices, wherein the device is selected from a labeling device, a purification device, a manipulation device, a radiation protection device, an analysis device, or an administration device.
Citation Information
Patent Citations
FAP inhibitor
WO2019154886A1
Compounds comprising a fibroblast activation protein ligand and use thereof
WO2022148843A1
Therapeutic drug targeting fibroblast activating protein and preparation method thereof
CN113621021A
Compounds comprising fibroblast activating protein ligands and uses thereof
CN114341158A
Cited By
FAP-targeting compound and use thereof
WO2026195063A1
